About The Joint (NASDAQ:JYNT)
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2017, the company operated 352 franchised clinics and 47 company-owned or managed clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Industry, Sector and Symbol
Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JYNT
CUSIPN/A
Phone480-245-5960
Debt
Debt-to-Equity Ratio0.20%
Current Ratio1.34%
Quick Ratio1.34%
Price-To-Earnings
Trailing P/E Ratio-29.00
Forward P/E Ratio90.63
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.16 million
Price / Sales3.92
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book20.14
Profitability
EPS (Most Recent Fiscal Year)($0.25)
Net Income$-3,270,000.00
Net Margins-13.01%
Return on Equity-66.74%
Return on Assets-20.11%
Miscellaneous
Employees148
Outstanding Shares13,590,000
The Joint (NASDAQ:JYNT) Frequently Asked Questions
What is The Joint's stock symbol?
The Joint trades on the NASDAQ under the ticker symbol "JYNT."
How were The Joint's earnings last quarter?
The Joint (NASDAQ:JYNT) released its quarterly earnings results on Thursday, March, 8th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The business had revenue of $6.93 million for the quarter, compared to the consensus estimate of $6.48 million. The Joint had a negative net margin of 13.01% and a negative return on equity of 66.74%. View The Joint's Earnings History.
When is The Joint's next earnings date?
What price target have analysts set for JYNT?
4 brokers have issued 12 month price objectives for The Joint's stock. Their predictions range from $5.70 to $9.00. On average, they expect The Joint's share price to reach $6.8167 in the next year. View Analyst Ratings for The Joint.
What are Wall Street analysts saying about The Joint stock?
Here are some recent quotes from research analysts about The Joint stock:
- 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (4/14/2018)
- 2. Maxim Group analysts commented, "4Q17 revenue of $6.93M, up 19.9% y/y, was above both our estimate of $6.62M and consensus of $6.64M. System-wide comp sales grew 26% y/y. GAAP EPS of ($0.02) was slightly narrower than both our estimate and consensus of ($0.03). 2018 guidance issued with revenue bracketing our estimates and above consensus, but adjusted EBITDA below both our estimates and consensus. JYNT plans to open 40-50 franchise clinics, add up to 2 new corporate-owned clinics (greenfields), and purchase up to 3 existing franchises (buybacks)." (3/9/2018)
Who are some of The Joint's key competitors?
Some companies that are related to The Joint include Xoma (XOMA), Veracyte (VCYT), Foamix Pharmaceuticals (FOMX), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Zafgen (ZFGN), Teligent (TLGT), Protagonist Therapeutics (PTGX), Spero Therapeutics (SPRO), Kamada (KMDA), Immune Design (IMDZ), Spring Bank Pharmaceuticals (SBPH), Proteostasis Therapeutics (PTI), Immupharma (IMM), Avid Bioservices (CDMO), Helius Medical Technologies (HSDT), SeaSpine (SPNE) and Intec Pharma (NTEC).
Who are The Joint's key executives?
The Joint's management team includes the folowing people:
- Mr. Peter D. Holt, Chief Exec. Officer, Pres and Director (Age 59)
- Mr. John P. Meloun, Chief Financial Officer (Age 41)
- Mr. Jorge Armenteros, VP of Operations
- Dr. James Edwards, Chief Chiropractic & Compliance Officer
- Ms. Donna Smith, VP of Marketing
When did The Joint IPO?
(JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.
Has The Joint been receiving favorable news coverage?
News stories about JYNT stock have been trending somewhat positive on Saturday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Joint earned a news impact score of 0.10 on Accern's scale. They also assigned media stories about the company an impact score of 45.31 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of The Joint?
Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is The Joint's stock price today?
One share of JYNT stock can currently be purchased for approximately $7.25.
How big of a company is The Joint?
The Joint has a market capitalization of $97.68 million and generates $25.16 million in revenue each year. The company earns $-3,270,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. The Joint employs 148 workers across the globe.
How can I contact The Joint?
The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]
MarketBeat Community Rating for The Joint (JYNT)
MarketBeat's community ratings are surveys of what our community members think about The Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
The Joint (NASDAQ:JYNT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for The Joint in the last 12 months. Their average twelve-month price target is $6.8167, suggesting that the stock has a possible downside of 5.98%. The high price target for JYNT is $9.00 and the low price target for JYNT is $5.70. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.8167 | $6.15 | $6.15 | $6.15 |
| Price Target Upside: | 5.98% downside | 23.25% upside | 65.32% upside | 65.32% upside |
The Joint (NASDAQ:JYNT) Consensus Price Target History
The Joint (NASDAQ:JYNT) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
The Joint (NASDAQ:JYNT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
The Joint (NASDAQ JYNT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 49.57%
The Joint (NASDAQ JYNT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/30/2017 | James H Amos Jr | Director | Buy | 10,000 | $3.85 | $38,500.00 | 57,295 |  |
| 6/30/2017 | Peter D Holt | Insider | Buy | 3,820 | $3.76 | $14,363.20 | 43,820 | |
| 6/27/2017 | John P. Meloun | CFO | Buy | 6,850 | $3.69 | $25,276.50 | | |
| 3/29/2017 | James H Amos Jr | Director | Buy | 10,000 | $3.98 | $39,800.00 | 29,345 | |
| 3/28/2017 | Glenhill Advisors Llc | Major Shareholder | Sell | 86,428 | $3.40 | $293,855.20 | | |
| 3/27/2017 | Glenhill Advisors Llc | Major Shareholder | Sell | 43,214 | $3.13 | $135,259.82 | | |
| 3/24/2017 | Peter D Holt | CEO | Buy | 10,000 | $3.52 | $35,200.00 | 40,000 | |
| 12/14/2016 | James H Amos Jr | Director | Buy | 10,000 | $2.22 | $22,200.00 | 27,345 | |
| 12/1/2016 | Bret Sanders | Director | Buy | 10,000 | $2.19 | $21,900.00 | 35,345 | |
| 9/22/2016 | David M Orwasher | Insider | Sell | 5,000 | $2.40 | $12,000.00 | 117,723 | |
| 9/12/2016 | David M Orwasher | Insider | Sell | 5,000 | $2.82 | $14,100.00 | 122,723 | |
| 9/7/2016 | David M Orwasher | Insider | Sell | 4,200 | $3.01 | $12,642.00 | 127,723 | |
| 9/2/2016 | David M Orwasher | Insider | Sell | 1,702 | $2.80 | $4,765.60 | 133,524 | |
| 8/29/2016 | Peter D Holt | CEO | Buy | 30,000 | $2.66 | $79,800.00 | 10,000 | |
| 8/29/2016 | Richard A Kerley | Director | Buy | 7,000 | $2.78 | $19,460.00 | 18,285 | |
| 8/26/2016 | Richard A Kerley | Director | Buy | 5,000 | $2.18 | $10,900.00 | 18,285 | |
| 8/9/2016 | David M Orwasher | Insider | Sell | 10,000 | $2.18 | $21,800.00 | 133,625 | |
| 7/11/2016 | David M Orwasher | Insider | Sell | 5,000 | $2.13 | $10,650.00 | 143,625 | |
| 7/1/2016 | Glenhill Advisors Llc | Major Shareholder | Buy | 80,069 | $1.97 | $157,735.93 | | |
| 6/29/2016 | David M Orwasher | Insider | Sell | 10,000 | $2.38 | $23,800.00 | 151,625 | |
| 6/27/2016 | David M Orwasher | Insider | Sell | 7,000 | $2.50 | $17,500.00 | 151,625 | |
| 6/20/2016 | David M Orwasher | Insider | Sell | 600 | $2.80 | $1,680.00 | 158,625 | |
| 6/10/2016 | David M Orwasher | Insider | Sell | 1,700 | $3.06 | $5,202.00 | 160,625 | |
| 6/8/2016 | David M Orwasher | Insider | Sell | 150 | $3.04 | $456.00 | 160,925 | |
| 6/6/2016 | David M Orwasher | Insider | Sell | 2,300 | $3.06 | $7,038.00 | 161,075 | |
| 6/2/2016 | David M Orwasher | Insider | Sell | 2,100 | $3.17 | $6,657.00 | 163,375 | |
| 6/1/2016 | David M Orwasher | Insider | Sell | 2,400 | $3.05 | $7,320.00 | 165,475 | |
| 3/30/2016 | Glenhill Advisors Llc | Major Shareholder | Buy | 46,465 | $3.10 | $144,041.50 | | |
| 3/30/2016 | James H Amos Jr | Director | Buy | 5,000 | $3.39 | $16,950.00 | 5,000 | |
| 3/29/2016 | Ronald V Davella | Director | Buy | 3,000 | $3.14 | $9,420.00 | 3,000 | |
| 3/28/2016 | John B Richards | CEO | Buy | 3,295 | $2.98 | $9,819.10 | 429,245 | |
| 3/23/2016 | Richard A Kerley | Director | Buy | 900 | $3.41 | $3,069.00 | 940 | |
| 3/22/2016 | Francis T Joyce | CFO | Buy | 2,000 | $3.27 | $6,540.00 | 95,500 | |
| 3/22/2016 | Steve Colmar | Director | Buy | 6,000 | $3.38 | $20,280.00 | 4,700 | |
| 3/21/2016 | Bret Sanders | Director | Buy | 7,580 | $3.26 | $24,710.80 | 13,000 | |
| 3/21/2016 | John B Richards | CEO | Buy | 7,450 | $3.31 | $24,659.50 | 425,950 | |
| 11/20/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 651,842 | $5.50 | $3,585,131.00 | | |
| 11/20/2015 | John B Richards | CEO | Buy | 18,000 | $5.50 | $99,000.00 | 418,500 | |
| 5/15/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 12,820 | $9.49 | $121,661.80 | | |
| 4/2/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 5,669 | $7.80 | $44,218.20 | | |
| 3/31/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 2,289 | $7.35 | $16,824.15 | | |
| 3/24/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 5,686 | $7.33 | $41,678.38 | | |
| 3/3/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 2,915 | $7.99 | $23,290.85 | | |
| 2/27/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 2,246 | $7.97 | $17,900.62 | | |
| 1/30/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 38,981 | $6.44 | $251,037.64 | | |
| 1/2/2015 | Glenhill Advisors Llc | Major Shareholder | Buy | 7,485 | $6.35 | $47,529.75 | | |
(Data available from 1/1/2013 forward)
The Joint (NASDAQ JYNT) News Headlines
| Source: |
|
The Joint (NASDAQ:JYNT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
The Joint (NASDAQ:JYNT) Income Statement, Balance Sheet and Cash Flow Statement
The Joint (NASDAQ JYNT) Stock Chart for Saturday, April, 21, 2018
Loading chart…
